Prolong Pharmaceuticals

About Prolong Pharmaceuticals

Prolong Pharmaceuticals, LLC, headquartered in South Plainfield, New Jersey, is a privately held biotech company specializing in the development of novel biologics aimed at treating Central Nervous System (CNS), hematology, and respiratory disorders. Established in 2005 as a research lab, Prolong has grown into a mature entity with an active clinical development program and a large-scale cGMP manufacturing facility. The company focuses on creating therapies that restore homeostasis by delivering targeted oxygenation to hypoxic tissues and reducing inflammation through innovative approaches like their PP 007 PEGylated carboxyhemoglobin bovine (PCHB), known as Sanguinate. This product is designed to improve tissue perfusion and reduce inflammation, offering a holistic solution to vascular and tissue homeostasis. Prolong's business model revolves around clinical trials and the development of a diverse product portfolio aimed at addressing debilitating comorbidities associated with reduced quality of life, increased medical costs, and significant mortality. The company serves patients who are part of their clinical trials, primarily targeting markets in stroke, hematology, and oncology. Revenue is generated through the development and eventual commercialization of these biologic therapies.